Norris Morrison, DPM
Podiatrist · Apple Valley, CANPI 1790098218
Payments from drug & device makers
Across 143 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$562
- Smith+Nephew$433
- Amgen$323
- Cardiovascular Systems Inc.$312
- Bioventus LLC$221
- Nevro Corp.$214
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,44699%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 32 | $562 |
| Smith+Nephew | 34 | $433 |
| Amgen(2 entities) | 15 | $323 |
| Cardiovascular Systems Inc. | 3 | $312 |
| Bioventus LLC | 6 | $221 |
| Nevro Corp. | 6 | $214 |
| Medtronic | 1 | $170 |
| Angiodynamics, Inc. | 2 | $150 |
| Pfizer | 2 | $146 |
| AbbVie(2 entities) | 5 | $98 |
| Organogenesis Inc. | 2 | $68 |
| Vaporox, Inc. | 1 | $63 |
| KCI USA, Inc. | 2 | $60 |
| Johnson & Johnson | 3 | $53 |
| Osiris Therapeutics Inc. | 4 | $53 |
| Zimmer Biomet | 2 | $53 |
| GSK | 3 | $53 |
| Integra Lifesciences Corporation | 2 | $53 |
| Stryker(2 entities) | 2 | $49 |
| Advanced Oxygen Therapy Inc. | 2 | $44 |
| Paratek Pharmaceuticals, Inc. | 2 | $37 |
| Averitas Pharma Inc. | 1 | $36 |
| Tactile Systems Technology Inc | 2 | $34 |
| Fidia Pharma USA Inc. | 1 | $34 |
| ERMI LLC | 2 | $34 |
| Kerecis Limited | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Radius Health, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,467 in reported general payments places this provider in the 75th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 486 | $25,909 |
| Naproxen | 114 | $11,325 |
| Diclofenac Sodium | 93 | $5,420 |
| Ciclopirox | 233 | $4,623 |
| SantylCollagenase Clostridium Hist. | 12 | $4,043 |
| Econazole Nitrate | 82 | $3,865 |
| Lidocaine | 58 | $2,226 |
| Ketoconazole | 47 | $2,153 |
| Gabapentin | 189 | $1,848 |
| Ammonium Lactate | 57 | $927 |
| Mupirocin | 87 | $665 |
| Clobetasol Propionate | 19 | $491 |
| Ibuprofen | 41 | $423 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 22 | $339 |
| Terbinafine Hcl | 36 | $226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $433 | $4,04312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 721 podiatrist providers in California.
Other podiatrist in Apple Valley
- Fardin HakakianTarzana$2.8M
- David GuzmanNapa$2.1M
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.6M
- David ArmstrongLos Angeles$1.4M
- Dean VayserCarlsbad$1.2M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
- Shawn CazzellFresno$788K
- Philip WrotslavskyPoway$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.